RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+52.23%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$3.55B
AUM Growth
+$3.55B
(+53%)
Cap. Flow
+$461M
Cap. Flow
% of AUM
12.97%
Top 10 Holdings %
Top 10 Hldgs %
48.38%
Holding
82
New
17
Increased
31
Reduced
8
Closed
5
Top Buys
| 1 |
Avidity Biosciences
RNA
|
$104M |
| 2 |
Baxter International
BAX
|
$83.5M |
| 3 |
CERN
Cerner Corp
CERN
|
$81.1M |
| 4 |
Axsome Therapeutics
AXSM
|
$49.8M |
| 5 |
10x Genomics
TXG
|
$39.8M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$94M |
| 2 |
Zimmer Biomet
ZBH
|
$67.9M |
| 3 |
Sarepta Therapeutics
SRPT
|
$51.8M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$36.8M |
| 5 |
STAAR Surgical
STAA
|
$22.6M |
Sector Composition
| 1 | Healthcare | 91.43% |
| 2 | Materials | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Rocket Pharmaceuticals
RCKT
$354M
| $352M | 9.9% | 16,812,491 | – | – |
|
2
Alnylam Pharmaceuticals
ALNY
$58.5B
| $249M | 7.01% | 1,681,645 | – | – |
|
3
PTC Therapeutics
PTCT
$3.92B
| $201M | 5.66% | 3,963,120 +30,374 | +0.8% | +$1.54M |
|
|
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $182M | 5.11% | 7,152,918 +189,783 | +3% | +$4.82M |
|
5
Adverum Biotechnologies
ADVM
$64.6M
| $142M | 3.99% | 6,790,027 +158,400 | +2% | +$3.31M |
|
6
Immunovant
IMVT
$2.56B
| $139M | 3.92% | 5,717,182 +1,291,076 | +29% | +$31.4M |
|
|
7
Axsome Therapeutics
AXSM
$6.05B
| $136M | 3.84% | 1,658,316 +605,347 | +57% | +$49.8M |
|
|
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $124M | 3.49% | 1,087,726 +102,560 | +10% | +$11.7M |
|
|
9
Avidity Biosciences
RNA
$5.99B
| $104M | 2.92% | +3,995,000 | New | +$104M |
|
|
MYOK
10
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $90.5M | 2.55% | 936,931 +156,033 | +20% | +$15.1M |
|
11
Masimo
MASI
$7.59B
| $88.6M | 2.49% | 388,776 +5,861 | +2% | +$1.34M |
|
12
Stoke Therapeutics
STOK
$1.08B
| $84.5M | 2.38% | 3,544,248 | – | – |
|
|
13
Baxter International
BAX
$12.7B
| $83.5M | 2.35% | +969,370 | New | +$83.5M |
|
|
CERN
14
DELISTED
Cerner Corp
CERN
| $81.1M | 2.28% | +1,182,409 | New | +$81.1M |
|
15
Natera
NTRA
$23.1B
| $76.2M | 2.14% | 1,529,128 +263,003 | +21% | +$13.1M |
|
|
TBIO
16
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $66.6M | 1.87% | 3,716,994 +24,570 | +0.7% | +$440K |
|
17
Relmada Therapeutics
RLMD
$37.2M
| $66.3M | 1.86% | 1,480,852 +496,310 | +50% | +$22.2M |
|
|
AXNX
18
DELISTED
Axonics, Inc. Common Stock
AXNX
| $66.1M | 1.86% | 1,883,257 +174,257 | +10% | +$6.12M |
|
19
Q32 Bio
QTTB
$20.9M
| $66.1M | 1.86% | 4,352,190 -47,060 | -1% | -$715K |
|
|
BLU
20
DELISTED
BELLUS Health Inc.
BLU
| $61.6M | 1.73% | 5,970,230 +479,238 | +9% | +$4.94M |
|
21
Protagonist Therapeutics
PTGX
$3.67B
| $59.7M | 1.68% | 3,383,208 +722,816 | +27% | +$12.8M |
|
22
Tandem Diabetes Care
TNDM
$845M
| $59.2M | 1.67% | 598,923 +155,198 | +35% | +$15.4M |
|
|
23
10x Genomics
TXG
$1.74B
| $56.8M | 1.6% | 636,092 +445,983 | +235% | +$39.8M |
|
|
OYST
24
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
| $55.1M | 1.55% | 1,909,360 +939,882 | +97% | +$27.1M |
|
25
Vericel Corp
VCEL
$1.83B
| $53.2M | 1.5% | 3,850,347 -610,408 | -14% | -$8.44M |
|